Original contributionPersistence of high-grade prostatic intra-epithelial neoplasia under combined androgen blockade therapy
References (16)
- et al.
Intraductal dysplasia: A premalignant lesion of the prostate
Hum Pathol
(1986) - et al.
The extent and multicentricity of high-grade prostatic intraepithelial neoplasia in clinically localized prostatic adenocarcinoma
Hum Pathol
(1997) - et al.
Decrease of prostatic intra-epithelial neoplasia following androgen deprivation therapy in patients with stage T3 carcinoma treated by radical prostatectomy
Urology
(1994) - et al.
Architectural patterns of high-grade prostatic intraepithelial neoplasia
Hum Pathol
(1993) - et al.
Prolonged neoadjuvant combined androgen blockade leads to a further reduction of prostatic tumor volume: three versus six months of endocrine therapy
Urology
(1999) - et al.
Prostatic intra-epithelial neoplasia and early invasion in prostate cancer
Cancer
(1987) High grade prostatic intra-epithelial neoplasia: The most likely precursor of prostate cancer
Cancer
(1995)- et al.
Effects of combination endocrine therapy on normal prostate, prostatic intra-epithelial neoplasia, and prostatic adenocarcinoma
J Clin Pathol
(1994)
There are more references available in the full text version of this article.
Cited by (0)
- 1
Prof. F. Labrie holds as co-inventor a patent on combined endocrine therapy of prostate cancer.
Copyright © 1999 Published by Elsevier Inc.